N-benzyloxycarbonyl-(L)-glutamic anhydride | 70185-68-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-benzyloxycarbonyl-(L)-glutamic anhydride
• 英文别名: N2-benzyloxycarbonyl-DL-glutamic anhydride；N-carbobenzyloxy-L-glutamic anhydride；N-carbobenzoxy-L-glutamic anhydride；(4S)-5-[(2S)-4-carboxy-2-(phenylmethoxycarbonylamino)butanoyl]oxy-5-oxo-4-(phenylmethoxycarbonylamino)pentanoic acid
• CAS: 70185-68-1
• 化学式: C₂₆H₂₈N₂O₁₁
• 分子量: 544.515
• InChiKey: QPCWVANVMONZDQ-PMACEKPBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  39
• 可旋转键数：
  18
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  195
• 氢给体数：
  4
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  N-benzyloxycarbonyl-(L)-glutamic anhydride 、 4,4-二甲基环己胺 在 sodium hydroxide 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 生成 1-(4,4-dimethylcyclohexyl)-N-carbobenzyloxy-L-glutamine
  参考文献：
  名称：

  Derivatives of glutamic and aspartic acids, a method of preparing them,

  摘要：

  化合物的普通式(I)和(II)，其中r为1或2，R.sub.2和R.sub.3独立地从H，CH.sub.3，C.sub.2 H.sub.5和CHO中选择，前提是R.sub.2和R.sub.3不同时为CHO，而R.sub.1从以下选择：氨基烷基金刚烷基，单环氨基烷基，双环氨基螺基，双环氨基（正融合），双环氨基，氮杂环烷基，氮杂双环基（正融合），双环氮杂螺基，氮杂双环基和氮杂环烷基，以及线性或支链氨基烷基。

  公开号：

  US05723494A1

文献信息

• [EN] NEW DERIVATIVES OF GLUTAMIC AND ASPARTIC ACIDS, A METHOD OF PREPARING THEM, AND THEIR USE AS DRUGS FOR ENHANCING MEMORY AND LEARNING<br/>[FR] NOUVEAUX DERIVES DES ACIDES GLUTAMIQUE ET ASPARTIQUE, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION COMME MEDICAMENTS AMELIORANT LA MEMOIRE ET L'APPRENTISSAGE
  申请人：ROTTA RESEARCH LABORATORIUM S.P.A.

  公开号：WO1994020454A1

  公开（公告）日：1994-09-15

  (EN) Compounds represented by general formulae (I) and (II), in which r is 1 or 2, R2 and R3 are selected independently from H, CH3, C2H5 and CHO, provided that R2 and R3 are not simultaneously CHO, and in which R1 is selected from: an aminoalkyl adamantyl group, a monocyclic aminoalkyl group, a dicyclic aminospiro group, a dicyclic amino group (orthofused), a dicyclic amino group, and azacycloalkyl group, an azadicyclic group (orthofused), a dicyclic azaspiro group, and azadicyclic group, and azacycloalkyl group, and a linear or branched aminoalkyl group.(FR) Composés répondant aux formules générales (I) et (II), dans lesquelles r représente 1 ou 2; R2 and R3, indépendamment l'un de l'autre, représentent H, CH3, C2H5 ou CHO, à condition que R2 et R3 ne représentent pas simultanément CHO; et R1 représente un groupe adamantyle aminoalkyle, un groupe aminoalkyle monocyclique, un groupe aminospiro bicyclique, un groupe amino bicyclique (orthofusionné), un groupe amino bicyclique, un groupe azacycloalkyle, un groupe azabicyclique (orthofusionné), un groupe azaspiro bicyclique, un groupe azabicyclique, un groupe azacycloalkyle, ou un groupe aminoalkyle ramifié.

  (中) 由一般式(I)和(II)所代表的化合物，其中r为1或2，R2和R3独立选择自H，CH3，C2H5和CHO，但要求R2和R3不能同时为CHO。而R1则从以下选取：氨基烷基金刚烷基，单环氨基烷基，双环氨基螺基，双环氨基基（正融合），双环氨基基，氮杂环烷基，氮杂双环基（正融合），双环氮杂螺基，氮杂双环基，氮杂环烷基，线性或支链氨基烷基。
• Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents
  申请人：ZENECA LIMITED

  公开号：US20020119968A1

  公开（公告）日：2002-08-29

  The invention concerns compounds of formula (I) 1 wherein each of G 1 , G 2 and G 3 is CH or N; m is 1 or 2; R 1 includes hydrogen, halogeno and (1-4C)alkyl; M 1 is a group of the formula: NR 2 —L 1 —T 1 R 3 in which R 2 and R 3 together form a (1-4C)alkylene group, L 1 includes (1-4C)alkylene, and T 1 is CH or N; A may be a direct link; M 2 is a group of the formula: (T 2 R 4 ) r —L 2 —T 3 R 5 in which r is 0 or 1, each of T 2 and T 3 is CH or N, each of R 4 and R 5 is hydrogen or (1-4C)alkyl, or R 4 and R 5 together form a (1-4C)alkylene group, and L 2 includes (1-4C)alkylene; M 3 may be a direct link to X; X includes sulphonyl; and Q includes naphthyl and a heterocyclic moiety; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use as antithrombotic or anticoagulant agents.

  本发明涉及式(I)的化合物，其中G1、G2和G3中的每一个是CH或N；m为1或2；R1包括氢、卤素和(1-4C)烷基；M1是公式NR2-L1-T1R3的基团，在其中R2和R3共同形成一个(1-4C)烷基，L1包括(1-4C)烷基，T1是CH或N；A可以是直接连接；M2是公式(T2R4)r-L2-T3R5的基团，在其中r为0或1，T2和T3中的每一个是CH或N，R4和R5中的每一个是氢或(1-4C)烷基，或者R4和R5共同形成一个(1-4C)烷基，L2包括(1-4C)烷基；M3可以是直接连接到X；X包括磺酰基；Q包括萘基和杂环基；或其药学上可接受的盐；制备它们的方法，含有它们的制药组合物以及它们作为抗血栓或抗凝剂剂的用途。
• Methods and apparatus for accelerated orthokeratology
  申请人：——

  公开号：US20010016731A1

  公开（公告）日：2001-08-23

  An accelerated method of orthokeratology includes the steps of softening of the cornea with a softening agent, applying a mold to reshape the cornea to a desired anterior curvature, and rapidly restabilizing or “fixing” the corneal tissues so that the cornea retains its new configuration. A chemical softening agent, such as glutaric anhydride is applied to the cornea to soften the cornea, after which a specially designed mold of predetermined curvature and configuration is applied to the cornea. Slight downward pressure is applied to the mold for a predetermined period of time to re-shape the cornea. The mold is maintained in position while a stabilizing agent, such as a UV light source, is positioned above the mold. The stabilizing agent, i.e. UV light, is applied to the cornea for a predetermined time, wherein the stabilizing agent immediately restabilizes the corneal tissue so that the cornea immediately retains its shape upon removal of the mold. The stabilization process can also be used for patients having already undergone traditional orthokeratology to eliminate the need to continue wearing a retainer to maintain the shape of the cornea.

  角膜矫形术的加速方法包括以下步骤：用软化剂软化角膜，使用模具将角膜重塑成所需的前弧度，并迅速重新稳定或 "固定 "角膜组织，使角膜保持新的形态。在角膜上涂抹化学软化剂（如戊二酸酐）以软化角膜，然后在角膜上涂抹专门设计的具有预定弧度和结构的模具。在预定时间内对模具施加轻微的向下压力，以重新塑形角膜。将稳定剂（如紫外线光源）置于模具上方时，模具将保持在原位。将稳定剂（即紫外线）照射到角膜上，持续预定的时间，其中稳定剂会立即重新稳定角膜组织，使角膜在移除模具后立即保持其形状。稳定过程也可用于已接受传统角膜矫形术的患者，使其无需继续佩戴保持器来保持角膜的形状。
• Viscoelastic collagen solution for ophthalmic use and method of preparation
  申请人：MINNESOTA MINING AND MANUFACTURING COMPANY

  公开号：EP0214853B1

  公开（公告）日：1994-11-30
• AMINO ACID TRANSPORT PROTEINS, AMINO ACID ANALOGUES, ASSAY APPARATUS, USES THEREOF FOR TREATMENT AND DIAGNOSIS OF CANCER
  申请人：AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED

  公开号：EP0436612A1

  公开（公告）日：1991-07-17